Head-to-head · WeighScore
Invyncible vs Kin Meds
The verdict
Kin Meds takes it — 69.1/100 to 61/100.
Kin Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Kin Meds is a LegitScript-verified telehealth platform offering both compounded GLP-1s (semaglutide from $199/mo, tirzepatide from $249/mo) and brand-name FDA-approved options including Wegovy injection and pill, Zepbound and Foundayo from $149/mo.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Invyncible | Kin Meds |
|---|---|---|
| WeighScore | 61/100 | 69.1/100 |
| Grade | C | C |
| Scorecard rank | #335 | #149 |
| Semaglutide | $149/mo (0.45 mg dose, compounded with glycine + B12) | $149/mo (brand Wegovy) |
| Tirzepatide | $180/mo (2.5 mg weekly, 4-week program, compounded) | $149/mo (brand Zepbound) |
| Coverage | 46 states plus DC | Coverage not published |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Yes |
Graded #335 · C
Strengths
- Publishes the price of every dose program openly, with no account and no intake first
- Names its six compounding pharmacies with addresses and phone numbers and lets patients choose between them, or bring their own
- Marks compounded against FDA-approved brand and injection against oral on the catalog itself — Wegovy $1,750, Zepbound $1,540, oral capsules $255.50
- Refills are requested rather than auto-billed, and the card is charged only on provider approval
- Corporate parent disclosed (Nationwide Telemedicine, LLC) with a published St. Petersburg, FL address and a working LegitScript link
Where it loses points
- The advertised figure is the starter vial — plain compounded semaglutide reaches $262.50 and then $350 as the vial size grows, per the site's own FAQ
- Every listed price is struck through from a higher one that never expires, which is anchoring rather than a discount
- The six named pharmacies are named without a 503A or 503B designation anywhere
- Shipping cost is unpublished and refrigerated programs get only overnight cold shipping
- Six states lose compounded semaglutide and seven lose tirzepatide, against a 46-state company footprint
Graded #149 · C
FDAWarning letter issued to Kin Meds in February 2026. See the FDA warning-letter database.
Strengths
- Publicly lists $199/mo compounded semaglutide and $249/mo compounded tirzepatide
- Brand-name options too — Wegovy injection and pill, Zepbound, Foundayo from $149/mo entry pricing
- LegitScript verified
- Clearly identifies itself as the intake platform and a licensed third-party pharmacy as the dispenser
- Broad longevity menu (Sermorelin, NAD+, Glutathione) plus TRT, hair, skin, and sexual health
Where it loses points
- Legal entity name and state of incorporation not publicly disclosed
- The third-party pharmacy partner isn't named, and Kin Meds isn't itself a licensed pharmacy
- Per-state availability not listed
- $149/mo brand pricing is the insured entry tier — cash-pay patients should expect higher real costs
- FDA issued Kin Meds a warning letter in February 2026; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 544 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.